Get the content you want anytime you want.
REGISTER NOW | SIGN IN
VIDEO

What Were the Results of the Phase 3 EMERALD Trial?

SEP 25, 2017 | CONTAGION® EDITORIAL STAFF


Magda Opsomer, MD, director, clinical Leader, Infectious Diseases and Vaccines, Janssen Pharmaceutical Companies, Belgium, provides some insight into the phase 3 EMERALD trial regarding individuals infected with HIV who are suppressed on their treatment. Dr. Opsomer shares that the results are favorable and the fact that it is a single-tablet regimen may work to improve adherence to treatment. Dr. Opsomer also shares some of the “high points” of the study. Recently, Janssen Research & Development submitted a new drug application to the US Food and Drug Administration for the new darunavir-based regimen.
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.


FEATURED
Big advances in treatment can